Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

Barr virus (EBV), known for causing mononucleosis, might also be involved in triggering multiple sclerosis (MS). Recent ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has directed Zydus ...

Moderna had hoped its shot would be at least 49% effective at preventing CMV infections, substantially reducing the risk of ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...

Moderna said its cytomegalovirus (CMV) vaccine didn't meet the primary efficacy endpoint in a Phase 3 trial, and it is discontinuing the clinical development program.

Moderna halts late-stage CMV vaccine trial after unmet goals but maintains 2025 financial outlook. Read more here.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.